397 results on '"Lewis, Basil S."'
Search Results
2. Oral anticoagulation in patients with left ventricular thrombus – a systematic review and meta-analysis
3. SGLT2 inhibitors in acute myocardial infarction: what can we learn from the DAPA-MI trial? More news from AHA
4. First-in-human trial of PCSK9 gene editing therapy for lowering cholesterol: a new frontier in cardiovascular pharmacotherapy? News from AHA
5. Timing of Staged Nonculprit Artery Revascularization in Patients With ST-Segment Elevation Myocardial Infarction: COMPLETE Trial
6. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
7. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin
8. Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial
9. Sustained Pericarditis Recurrence Risk Reduction With Long-Term Rilonacept.
10. GLP-1 receptor agonists: new game changing drugs in patients with heart failure with preserved ejection fraction and obesity
11. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
12. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
13. Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?
14. Pericardial Late Gadolinium Enhancement and Time to Recurrence: A Substudy from RHAPSODY, a Phase 3 Clinical Trial of Rilonacept in Recurrent Pericarditis
15. Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial
16. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial
17. Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI)
18. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial
19. Guía ESC 2020 sobre el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST: Grupo de Trabajo de la Sociedad Europea de Cardiología (ESC) para el diagnóstico y tratamiento del síndrome coronario agudo (SCA) en pacientes sin elevación persistente del segmento ST
20. Guía ESC 2020 para el tratamiento de las cardiopatías congénitas del adulto
21. Automated Computer-Assisted Diagnosis of Obstructive Coronary Artery Disease in Emergency Department Patients Undergoing 256-Slice Coronary Computed Tomography Angiography for Acute Chest Pain
22. Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study
23. Low cardiorespiratory fitness and coronary artery calcification: Complementary cardiovascular risk predictors in asymptomatic type 2 diabetics
24. Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis
25. SGLT2 inhibitors in acute myocardial infarction: what can we learn from the DAPA-MI trial? More news from American Heart Association Scientific Meeting
26. Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events
27. Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER
28. Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial
29. Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial
30. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)
31. Cardiac Computed Tomography Angiographic Findings as Predictors of Late Heart Failure in an Asymptomatic Diabetic Cohort: An 8-Year Prospective Follow-Up Study
32. Abstract 16714: Characterization of Types and Sizes of Myocardial Infarction Reduced With Evolocumab in FOURIER
33. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
34. Abstract 47: Tapering And Discontinuation Of Background Therapies During The Transition To Rilonacept Monotherapy In Rhapsody, A Phase 3 Clinical Trial Of Rilonacept In Patients With Recurrent Pericarditis
35. Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial
36. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
37. Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis.
38. Are SGLT2 inhibitors effective against ‘all’ heart failure with preserved ejection fraction?
39. The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials
40. Pro
41. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease
42. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease
43. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
44. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology
45. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)
46. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study
47. 2020 ESC Guidelines on the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndrome Working Group of the European Society of Cardiology (ESC) for the diagnosis and treatment of acute coronary syndrome (ACS) in patients without persistent ST segment elevation
48. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)
49. Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
50. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.